Tanvex BioPharma, Inc. (TPE:6541)

Tanvex BioPharma Ratios and Metrics

Market cap in millions TWD. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr 1, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Capitalization	11,098	14,565	10,697	8,715	12,377	20,476
Market Cap Growth	-37.87%	36.15%	22.75%	-29.59%	-39.55%	106.96%
Enterprise Value	11,797	14,718	11,603	9,691	13,133	19,692
Last Close Price	41.90	55.00	64.66	63.95	101.30	167.69
PS Ratio	27.68	36.32	308.48	141.91	552.43	3787.62
PB Ratio	1.95	2.56	11.98	10.61	8.90	7.33
P/TBV Ratio	4.83	6.34	12.07	10.66	8.97	7.35
EV/Sales Ratio	29.42	36.71	334.59	157.80	586.21	3642.61
Debt / Equity Ratio	0.28	0.28	1.85	2.11	1.32	0.63
Net Debt / Equity Ratio	0.12	0.12	1.42	1.65	0.76	-0.17
Net Debt / EBITDA Ratio	-0.56	-0.56	-1.01	-0.68	-0.71	0.31
Net Debt / FCF Ratio	-0.42	-0.42	-1.01	-0.90	-0.74	0.33
Asset Turnover	0.08	0.08	0.01	0.02	0.01	0.00
Inventory Turnover	2.65	2.65	0.16	0.01	0.32	0.03
Quick Ratio	1.30	1.30	1.17	1.15	2.68	9.06
Current Ratio	1.87	1.87	1.94	1.66	3.44	9.66
Return on Equity (ROE)	-45.55%	-45.55%	-161.17%	-193.18%	-78.41%	-56.99%
Return on Assets (ROA)	-16.22%	-16.22%	-30.84%	-42.47%	-24.68%	-22.00%
Return on Capital Employed (ROCE)	-19.40%	-19.40%	-56.80%	-87.50%	-51.50%	-35.80%
Earnings Yield	-13.52%	-10.30%	-12.91%	-24.52%	-13.26%	-7.54%
FCF Yield	-15.08%	-11.49%	-11.75%	-17.29%	-11.53%	-6.92%
Buyback Yield / Dilution	-57.76%	-57.76%	-20.44%	-9.60%	-8.31%	-21.32%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.